RCS - Envision Pharma Grp - Envision Pharma Names Dr. Jennifer Costello as CMO

Bristol-Myers Squibb CoAnnouncement

04/05/2023 13:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230504:nRSD1530Ya&default-theme=true

RNS Number : 1530Y  Envision Pharma Group  04 May 2023

Envision Pharma Group Appoints Healthcare Industry Expert and Experienced
Leader Dr. Jennifer Costello, PharmD, BCPS, CMPP, as Chief Medical Officer

PHILADELPHIA, PA / ACCESSWIRE / May 4, 2023 / Envision Pharma Group
(Envision) has appointed Dr. Jennifer Costello, PharmD, BCPS, CMPP, to the
role of Chief Medical Officer. Jennifer will be responsible for progressing
work across all sectors of Envision's business, including Technology, Medical,
Commercial, Public Affairs, and Value & Access and Data Analytics.

Meg Heim, CEO of Envision Pharma Group, adds, "I am so excited to welcome
Jennifer to the Envision team as Chief Medical Officer. Jennifer's deep
expertise in science and commercialization in the life sciences industry, in
addition to her extensive pharmaceutical understanding and experience will
further support the acceleration of our business expansion, mission, and
commitment to our vision as a technology-enabled partner to the life sciences
industry."

Jennifer is an accomplished pharmaceutical and healthcare leader with over 20
years of experience across the healthcare sector. She brings to this role
extensive cardiovascular, medical, and patient care-related focused expertise,
with a successful track record of leading high-performing cross-matrix teams
with global impact.

Prior to joining Envision, Jennifer held multiple leadership roles in global
medical affairs and publications, US HEOR publications, and global scientific
content. She developed a reputation for leading successful partnerships with
cross-functional colleagues, advocacy partners, and academic groups that
resulted in building innovative programs that foster healthcare
transformation.

Jennifer joins Envision from Bristol Myers Squibb, where she most recently led
cardiovascular (CV) patient advocacy across its CV portfolio (early phase
assets to marketed products). She drove the development and execution of
global and US strategies for a successful launch of a first-in-class CV asset,
working across early asset development, commercial, and medical affairs teams.
For her work in this space, she was awarded the coveted "Innovation Award"
from BMS.

Before joining the pharmaceutical industry, her 16 years of experience as a
practicing clinical pharmacist was within the academic medical-teaching
hospital. Jennifer served in numerous roles as a pediatric critical care
specialist, adult ambulatory clinical care specialist, hospital administrator,
and as a Director of Clinical Pharmacy Services. Under a collaborative
practice agreement, she also led outpatient care optimization, directly
co-managing heart failure, antithrombotic, and diabetic patients.

Jennifer received her PharmD from Northeastern University, completed her ASHP
PGY-1 residency at the University of Arizona/University Medical Center, and
received her board certification as a pharmacotherapy specialist from the
American College of Clinical Pharmacy. She served in adjunct teaching
positions with Rutgers University and the University of Florida. She has
authored over 50 publications and posters and served as a pharmacy national
thought leader within the heart failure, antithrombotic, and diabetes
management space.

Jennifer adds, "I am delighted and humbled to join the Envision team during
this transformative time. I am looking forward to meeting and working with our
Envision family, customers, and partners. This is an exciting period for our
industry at large, and I am privileged to build upon our company vision,
award-winning technology, and innovation as medical affairs and global
healthcare communication leaders."

About Envision Pharma Group

Founded in 2001, Envision Pharma Group is a leading global technology-enabled
strategic solutions partner for the life sciences industry, working with over
200 pharma and biotech companies, including 18 of the top 20 pharmaceutical
companies. Envision supports clients across the product life cycle through a
comprehensive suite of services and industry-leading technology solutions that
include artificial intelligence and natural language processing,
commercialization and integrated strategic consulting, evidence-based
scientific communications and engagement, HEOR/market access and data
analytics, medical capabilities, and omnichannel solutions. Learn more
at www.envisionpharmagroup.com (https://pr.report/iC8jM-rI) .

Contact Information

Colleen Carter

Associate Director, Communications, Office of the CEO
colleen.carter@envisionpharma.com (mailto:colleen.carter@envisionpharma.com)

1 (508) 505 8856

SOURCE: Envision Pharma Group

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEADSAEAADEFA